Introduction In recent discussions about the future of pharmaceutical research in the UK, Sir John Bell’s insights have raised critical concerns. His warning comes against the backdrop of Merck’s decision to close its proposed £1bn research center in King’s Cross, London. This decision highlights significant worries about the UK’s competitiveness in attracting global pharmaceutical investments.…